Roman Podoba, Helena Česáková, Marián Hatala, Jaroslav Fabčin, Marián Chrenšť
Approximately 25 % of colorectal cancer patients is diagnosed with metastatic disease. Their 5-year survival is less than 5 %. Currently available cytotoxic drugs (oxaliplatin, capecitabine, irinotecan) prolonged median survival of metastatic colorectal cancer (mCRC) patients from 4 - 6 months to 19 - 20 months. Recently, it is possible to use also targeted therapy for the treatment of cancer patients. For the mCRC treatment, there are 2 monoclonal antibodies available – bevacizumab and cetuximab. In this case report we describe good efficacy of the 1st line treatment – combination of chemotherapy and targeted therapy – bevacizumab (Avastin®) in patient with colorectal cancer and multiple hepatic metastasis.